IAG, the Image Analysis Group has partnered with the academics from the Faculty of Medicine and Health of the University of Leeds, UK to commercialise proprietary IP and research into imaging biomarkers for scleroderma; the venture has already received initial funding.
First Clinical Study with Novel Serotype E Botulinum Toxin Confirmed Favorable Safety and Differentiated Efficacy Profile
First Clinical Study with Novel Serotype E Botulinum Toxin Confirmed Favorable Safety and Differentiated Efficacy Profile
Aligned interests bond ex-U.S. investors and U.S. biotechs, but not without friction
NEWPORT BEACH, CA, USA – April 14, 2017 – Bonti, a privately-held, clinical-stage biotechnology company, today announced it successfully secured $11.7 million in a Series B financing. Proceeds from the round will be used to continue developing EB-001, a unique botulinum neurotoxin, for its targeted aesthetic and therapeutic indications with multi-billion dollar addressable market opportunities.
